Kavanaugh, A., Cutolo, M., Mease, P., Gladman, D., Adebajo, A., Gomez-Reino, J., Wollenhaupt, J., Schett, G., Lespessailles, E., Hu, C., Stevens, R., Edwards, C., & Birbara, C. (2014). oP0078 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-WEEK) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials. Annals of the rheumatic diseases, 73, 90–91. http://access.bl.uk/ark:/81055/vdc_100135148040.0x00005c